Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

withdrawn150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_2

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

NCT01559129
withdrawnphase_2

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT01135199

Clinical Trials (2)

Showing 2 of 2 trials
NCT01559129Phase 2

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Terminated
NCT01135199Phase 2

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2